Candida auris for the Clinical Microbiology Laboratory: Not Your Grandfather's Candida Species

Lockhart, Shawn R.; Berkow, Elizabeth L.; Chow, Nancy A.; Welsh, Rory M.

doi:10.1016/j.clinmicnews.2017.06.003

Cited by 89 publications

(93 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Bruker Biotyper (Bruker Daltonik GmbH, Bremen, Germany) and the VITEK MS (bioMérieux, Marcy, L'Etoile, France) include C. auris in their Research Use Only and certain versions of their FDA-approved system databases [3,5,11]. If MALDI-TOF is not available, laboratories can reliably identify an isolate by sequencing the D1-D2 region of the 28s rDNA or the internal transcribed spacer (ITS) regions of rDNA [12][13][14]. A confirmatory test such as cornmeal agar may be warranted for these species.…”

Section: Candida Auris Identificationmentioning

confidence: 99%

“…• Supplemented or modified media has been shown to be useful for C. auris screening [7][8][9]. • MALD-TOF and sequencing of D1-D2 region of the 28s rDNA or the internal transcribed region (ITS) of rDNA are recommended for an accurate identification of C. auris [12][13][14]. For phenotypic yeast identification, the VITEK 2 system (bioMérieux, Marcy, L'Etoile, France) included C. auris in its recent software upgrade (version 8.01).…”

Section: Candida Auris Identificationmentioning

confidence: 99%

See 1 more Smart Citation

Candida auris: A Review of Recommendations for Detection and Control in Healthcare Settings

Cáceres

Forsberg

Welsh

et al. 2019

JoF

Self Cite

View full text Add to dashboard Cite

Candida auris is an emerging multidrug-resistant fungal pathogen. Since first reported in 2009, C. auris has caused healthcare outbreaks around the world, often involving high mortality. Identification of C. auris has been a major challenge as many common conventional laboratory methods cannot accurately detect it. Early detection and implementation of infection control practices can prevent its spread. The aim of this review is to describe recommendations for the detection and control of C. auris in healthcare settings. most common misidentifications based on frequently used yeast identification methods [5,6]. However, efforts to improve C. auris identification methods have made substantial progress in the last few years. The development of a high-salt, high-temperature enrichment culture-based method has made it possible to reliably isolate C. auris from complex sample types [7][8][9]. Once an isolate is obtained, identification of C. auris can be efficiently accomplished with matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. For MALDI-TOF identification, it is important to ensure C. auris is in the reference database [5,6,10]. The Bruker Biotyper (Bruker Daltonik GmbH, Bremen, Germany) and the VITEK MS (bioMérieux, Marcy, L'Etoile, France) include C. auris in their Research Use Only and certain versions of their FDA-approved system databases [3,5,11]. If MALDI-TOF is not available, laboratories can reliably identify an isolate by sequencing the D1-D2 region of the 28s rDNA or the internal transcribed spacer (ITS) regions of rDNA [12][13][14].

show abstract

Section: Candida Auris Identificationmentioning

confidence: 99%

Section: Candida Auris Identificationmentioning

confidence: 99%

Candida auris: A Review of Recommendations for Detection and Control in Healthcare Settings

Cáceres

Forsberg

Welsh

et al. 2019

JoF

Self Cite

View full text Add to dashboard Cite

show abstract

“…auris spectra. Other databases constructed for species identification include Quest Diagnostics' CMdb and CDC's Microbe Net …”

Section: Laboratory Diagnosismentioning

confidence: 99%

Diagnosis, management and prevention of Candida auris in hospitals: position statement of the Australasian Society for Infectious Diseases

Ong

Chen

Clark

et al. 2019

Internal Medicine Journal

View full text Add to dashboard Cite

Candida auris is an emerging drug‐resistant yeast responsible for hospital outbreaks. This statement reviews the evidence regarding diagnosis, treatment and prevention of this organism and provides consensus recommendations for clinicians and microbiologists in Australia and New Zealand. C. auris has been isolated in over 30 countries (including Australia). Bloodstream infections are the most frequently reported infections. Infections have crude mortality of 30–60%. Acquisition is generally healthcare‐associated and risks include underlying chronic disease, immunocompromise and presence of indwelling medical devices. C. auris may be misidentified by conventional phenotypic methods. Matrix‐assisted laser desorption ionisation time‐of‐flight mass spectrometry or sequencing of the internal transcribed spacer regions and/or the D1/D2 regions of the 28S ribosomal DNA are therefore required for definitive laboratory identification. Antifungal drug resistance, particularly to fluconazole, is common, with variable resistance to amphotericin B and echinocandins. Echinocandins are currently recommended as first‐line therapy for infection in adults and children ≥2 months of age. For neonates and infants <2 months of age, amphotericin B deoxycholate is recommended. Healthcare facilities with C. auris should implement a multimodal control response. Colonised or infected patients should be isolated in single rooms with Standard and Contact Precautions. Close contacts, patients transferred from facilities with endemic C. auris or admitted following stay in overseas healthcare institutions should be pre‐emptively isolated and screened for colonisation. Composite swabs of the axilla and groin should be collected. Routine screening of healthcare workers and the environment is not recommended. Detergents and sporicidal disinfectants should be used for environmental decontamination.

show abstract

“…Worldwide mortality rates for disease cases with C. auris infections of the bloodstream approach 50%. Concern about the emergence and spread of C. auris has resulted in alerts being posted by the CDC (Centers for Disease Control and Prevention, USA), the ECDC (European Centre for Disease Prevention and Control, Sweden), and PHE (Public Health England, UK) 3–5 .…”

Section: Introductionmentioning

confidence: 99%

The mycoparasitic yeast Saccharomycopsis schoenii predates and kills multi-drug resistant Candida auris

Junker

Ruiz

Lorenz

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Candida auris has recently emerged as a multi-drug resistant fungal pathogen that poses a serious global health threat, especially for patients in hospital intensive care units (ICUs). C. auris can colonize human skin and can spread by physical contact or contaminated surfaces and equipment. Here, we show that the mycoparasitic yeast Saccharomycopsis schoenii efficiently kills both sensitive and multi-drug resistant isolates of C. auris belonging to the same clade, as well as clinical isolates of other pathogenic species of the Candida genus suggesting novel approaches for biocontrol.

show abstract

Candida auris for the Clinical Microbiology Laboratory: Not Your Grandfather's Candida Species

Cited by 89 publications

References 26 publications

Candida auris: A Review of Recommendations for Detection and Control in Healthcare Settings

Candida auris: A Review of Recommendations for Detection and Control in Healthcare Settings

Diagnosis, management and prevention of Candida auris in hospitals: position statement of the Australasian Society for Infectious Diseases

The mycoparasitic yeast Saccharomycopsis schoenii predates and kills multi-drug resistant Candida auris

Contact Info

Product

Resources

About